{"entity":{"id":"nct04793958","kind":"trial","name":"Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)","aka":["KRYSTAL-10"],"tldr":"A phase 3 trial of Cetuximab in colorectal cancer, run by Mirati Therapeutics Inc., active and no longer recruiting.","summary":"Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10) is a phase 3 interventional study registered as NCT04793958 by Mirati Therapeutics Inc., with 461 participants enrolled, started 2021-06-24 and due to reach its primary completion in 2026-01-16. Interventions recorded: MRTX849, Cetuximab, mFOLFOX6 Regimen, FOLFIRI Regimen. Conditions listed: Advanced Colorectal Cancer, Metastatic Colorectal Cancer. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04793958","url":"https://clinicaltrials.gov/study/NCT04793958"}],"tags":["ctgov-ingest"],"related":[],"cancers":["colorectal","kras-g12c-colorectal"],"sections":[],"technologies":["monoclonal-antibody"],"targets":[],"drugs":["cetuximab"],"companies":["bms"],"institutions":[],"pathways":[],"terms":[],"trials":["codebreak-300"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["KRYSTAL-10 is the randomised confirmatory trial for the June 2024 accelerated approval of adagrasib with cetuximab. The registry lists 461 participants, phase 3, sponsored by Mirati Therapeutics, and the status on 24 September 2026 was active but no longer recruiting: second-line adagrasib with cetuximab against investigator-choice chemotherapy (mFOLFOX6 or FOLFIRI) in KRAS G12C-mutated metastatic colorectal cancer."],"nct":"NCT04793958","phase":"3","setting":"A Randomized Phase 3 Study of MRTX849 in Combination With Cetuximab Versus Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation With Disease Progression On or After Standard First-Line Therapy","sponsor":"Mirati Therapeutics Inc.","started":"2021-06-24","startedType":"actual","yearReported":2026,"enrolled":461,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04793958/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"kras-g12c-colorectal","kind":"cancer","name":"KRAS G12C-mutant colorectal cancer","route":"/cancers/kras-g12c-colorectal/"}],"technology":[{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"}],"drug":[{"id":"cetuximab","kind":"drug","name":"Cetuximab","route":"/drugs/cetuximab/"}],"company":[{"id":"bms","kind":"company","name":"Bristol Myers Squibb","route":"/companies/bms/"}],"trial":[{"id":"codebreak-300","kind":"trial","name":"CodeBreaK 300","route":"/trials/codebreak-300/"}]}}